Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12236636

Donepezil for memory dysfunction in schizophrenia.

Andrew K Howard·Allen E Thornton·Siemion Altman·William G Honer
View original source ↗Export metadata ↓

Abstract

A case is reported of a 54-year-old female patient with schizophrenia and cognitive impairment. Her memory dysfunction improved following the addition of donepezil to quetiapine. The possible implications for future studies are reviewed.

Explore related subjects

Antipsychotic AgentsChronic DiseaseDibenzothiazepinesDonepezilDrug Therapy, CombinationFemaleFollow-Up StudiesHumansIndansMental RecallMiddle AgedNeuropsychological TestsNootropic AgentsPiperidinesQuetiapine FumarateRetention, PsychologySchizophreniaSchizophrenic PsychologyCase ReportsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andrew K Howard, Allen E Thornton, Siemion Altman, William G Honer. 2002. Donepezil for memory dysfunction in schizophrenia.. https://doi.org/10.1177/026988110201600313

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗